Nasdaq:NXTC
NextCure, Inc.
A clinical-stage oncology company leveraging proprietary DNA sequencing technology to create personalized cancer therapies.
Key Metrics
Investment Thesis
Bull Case
Investors may be attracted by the potential of the NextCure Platform to revolutionize solid tumor treatment if clinical trials succeed, offering a first-mover advantage in a high-value oncology space. The recent decrease in annual losses suggests improving operational efficiency or successful milestone achievements that could attract strategic partnerships.
Bear Case
The absence of revenue and a massive accumulated deficit make the stock highly speculative with no guarantee of returning to profitability soon. Investors must consider the risk of total capital depletion, as the company relies on markable security proceeds and financing cash flows rather than organic growth.
About NextCure, Inc.
NextCure, Inc. (NXTC) is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer, with a primary emphasis on its NextCure Platform that utilizes next-generation sequencing to identify patient-specific biomarkers and develop targeted treatments.
Analysis
Management Discussion
Despite a reduction in net loss from -$74.7M in 2022 to -$55.7M in 2024, the company continues to operate at a significant cash deficit with operating cash flow of -$40.8M. Total assets remain relatively low at $80.9M while liabilities stand at $15.4M, suggesting the company is capitalizing primarily through financing activities rather than operational profitability.
Industry Overview
The global oncology market is rapidly evolving towards precision medicine, where therapies tailored to individual genetic profiles are becoming the standard for treating solid tumors. Companies like NextCure operate in a competitive landscape dominated by large pharmaceutical giants and established biotech firms with extensive pipelines and proven track records.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $75.9M | $67.6M | $59.7M |
| Operating Income | $-75.9M | $-67.6M | $-59.7M |
| R&D | $54.2M | $47.9M | $41.5M |
| G&A | $21.7M | $19.7M | $15.7M |
| Stock-Based Comp | $9.5M | $8.2M | $6.3M |
| D&A | $4.1M | $3.7M | $2.9M |
| Other OpEx | $0 | $0 | $2.5M |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-75.9M | $-67.6M | $-59.7M |
| Income Tax | $-1.2M | $-4.9M | $-4.1M |
| Continuing Ops | $-74.7M | $-62.7M | $-55.7M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-74.7M | $-62.7M | $-55.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-74.7M | $-62.7M | $-55.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $164.0M | $112.7M | $71.8M |
| Cash & Equivalents | $26.6M | $13.1M | $27.7M |
| Prepaid Expenses | $4.1M | $4.4M | $3.2M |
| Other Current Assets | $133.3M | $95.2M | $40.9M |
| Long-Term Assets | $20.2M | $15.3M | $9.1M |
| PP&E (Net) | $11.9M | $9.0M | $5.5M |
| Operating Leases | $5.0M | $4.4M | $3.3M |
| Other LT Assets | $3.3M | $1.9M | $332.0K |
| Total Assets | $184.2M | $128.0M | $80.9M |
| Current Liabilities | $9.1M | $6.9M | $9.6M |
| Accounts Payable | $4.3M | $2.3M | $5.4M |
| Current Leases | $518.0K | $656.0K | $796.0K |
| Other Current Liab | $4.3M | $3.9M | $3.4M |
| Long-Term Liabilities | $7.5M | $6.7M | $5.8M |
| LT Operating Leases | $6.6M | $5.9M | $5.2M |
| Other LT Liab | $899.0K | $785.0K | $661.0K |
| Total Liabilities | $16.6M | $13.6M | $15.4M |
| Shareholders' Equity | $167.5M | $114.4M | $65.5M |
| Paid-In Capital | $430.8M | $439.1M | $445.6M |
| Retained Earnings | $-261.8M | $-324.5M | $-380.1M |
| AOCI | $-1.5M | $-222.0K | $4.0K |
| Total L&E | $184.2M | $128.0M | $80.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-74.7M | $-62.7M | $-55.7M |
| Non-Cash Adjustments | $20.6M | $13.5M | $15.5M |
| Working Capital Changes | $290.0K | $-3.8M | $-658.0K |
| Cash from Operations | $-53.9M | $-53.0M | $-40.8M |
| Capital Expenditures | $2.1M | $820.0K | $474.0K |
| Cash from Investing | $68.0M | $39.3M | $55.3M |
| Cash from Financing | $200.0K | $154.0K | $144.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $14.3M | $-13.5M | $14.6M |
| Beginning Cash | $12.3M | $26.6M | $13.1M |
| Ending Cash | $26.6M | $13.1M | $27.7M |
Frequently Asked Questions
How does NextCure, Inc. make money?
The company's operations are primarily driven by its drug discovery and development efforts, specifically focusing on the NextCure Platform for identifying actionable mutations in solid tumors. Current financials reflect a single segment structure typical of pre-revenue biotech firms, with all reported expenses categorized under research and development activities.
What are the main risks for NXTC?
Significant financial risk exists due to the substantial net loss of $55.7M in 2024 and a deep retained earnings deficit of -$380.1M, indicating heavy burn without current revenue streams. The company faces high regulatory and clinical trial risks inherent in developing novel cancer therapies without established market precedents. Dependence on external funding sources is critical given the lack of commercial revenue to support ongoing operations.
What is NXTC's competitive advantage?
The NextCure Platform offers a unique approach to treating solid tumors by directly targeting specific genetic mutations rather than relying on traditional biomarkers. The company's proprietary technology allows for the rapid identification of patient-specific targets, potentially accelerating clinical trial success rates compared to conventional drug discovery methods.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.